Pseudomonas calcis

Pseudomonas calcis: A Comprehensive Encyclopedic Reference

Overview and Prefatory Note on Scope

Pseudomonas calcis is a bacterium with a complex and somewhat obscure history in science. It appears in two distinct contexts that are important to keep conceptually separate: (1) its original identity as a historically named, calcium-carbonate-precipitating denitrifying microorganism studied in marine and soil microbiology since the early twentieth century, and (2) its contemporary appearance as one component among dozens of species listed in multi-organism soil-based organism (SBO) probiotic dietary supplement formulations. The scientific literature does not contain any clinical studies, toxicological dossiers, pharmacopeial monographs, or regulatory assessments that evaluate Pseudomonas calcis as an isolated, standalone dietary supplement ingredient. Any discussion of its "supplemental" use must therefore be contextualized accordingly: it exists as a minor listed constituent of complex multi-organism blends, and essentially all clinical data that peripherally relate to it pertain to the multi-organism formulas rather than to the organism individually. This article faithfully represents that evidentiary state.

Identity, Nomenclature, and Taxonomy

Original Discovery and Naming

Drew isolated a denitrifying bacterium able to form CaCO₃ crystals in liquid media and named it "Bacterium calcis" (later renamed Pseudomonas calcis). This original work was published by G. H. Drew in 1911 in a study titled "The action of some denitrifying bacteria in tropical and temperate seas and the bacterial precipitation of calcium carbonate in the sea," published in the Journal of the Marine Biological Association of the United Kingdom. Drew's memoir deals with the action of denitrifying bacteria in tropical seas, as well as the precipitation of calcium carbonate by marine bacteria, and the results are described as a significant contribution to the difficult subject of marine bacteriology.

Drew in 1911 suggested that marine denitrifying bacteria played an active role in the precipitation of calcium carbonates, with potential geological significance for this process. The organism he originally described was subsequently reclassified into the genus Pseudomonas, acquiring the binomial designation Pseudomonas calcis. Aragonite, one polymorph of calcium carbonate, occurs in the by-products of certain denitrifying bacteria described as "Bacterium calcis," or Pseudomonas calcis.

Current Taxonomic Status

Pseudomonas is a genus of Gram-negative, Gammaproteobacteria, belonging to the family Pseudomonadaceae. The genus has been subject to extensive phylogenomic revision. The members of the genus Pseudomonas demonstrate a great deal of metabolic diversity and are able to colonize a wide range of niches; 16S rRNA sequence analysis has redefined the taxonomy of many bacterial species, and as a result, the genus Pseudomonas includes strains formerly classified in the genera Chryseomonas and Flavimonas. Pseudomonas calcis does not appear as a validly described species in current major microbial taxonomy databases; it is considered an informal or historical name without a standing valid species designation under the International Code of Nomenclature of Prokaryotes.

Multiple historical Pseudomonas species have since been reclassified; for example, Pseudomonas acidovorans and Pseudomonas testosteroni have been reclassified as Comamonas acidovorans and Comamonas testosteroni, respectively, illustrating a broader taxonomic revision of the genus. The status of Pseudomonas calcis as a distinct, validly described species has not been confirmed by modern genomic methods, and it does not appear among the validly named type strains catalogued in major contemporary phylogenomic surveys of the genus.

Natural Sources and Ecological Niche

Pseudomonas species live in diverse environments and many are associated with higher organisms; species such as Pseudomonas putida and Pseudomonas fluorescens are rhizosphere-associated microbes considered plant-beneficial organisms. Pseudomonas is one of the many bacterial genera that is able to precipitate calcium, and this has been observed as the precipitation of calcium carbonate in several ureolytic Pseudomonas species and in certain P. aeruginosa strains.

Certain bacteria form crystals from the solutes in their aqueous environment, and some authors have associated this activity with the extensive deposits of CaCO₃ in places such as the Grand Bahama. Greenfield obtained aragonite crystals in cultures of Pseudomonas in an artificial seawater medium containing Na₂CO₃ or (NH₄)₂CO₃. In soil microbiology, Boquet et al. (1973) first demonstrated the precipitation of calcium carbonate by soil bacteria under laboratory conditions, with previous researchers having showed precipitation of carbonates by marine bacteria only in liquid media; Drew (1911) and Shinano (1972) investigated carbonate precipitation by soil bacteria on solid media, and among the organisms tested, several Bacillus strains and Pseudomonas aeruginosa were observed to form crystals.

Traditional and Historical Use

Pseudomonas calcis has no documented history of intentional traditional or ethnomedicinal use as a health-promoting preparation in any culture. It is a microorganism first described scientifically in the context of marine geology and microbiology in the early twentieth century. There are no historical records in herbalism, traditional Chinese medicine, Ayurveda, indigenous healing systems, or other traditional frameworks that reference this bacterium or any preparation derived from it for therapeutic purposes.

The broader concept of beneficial exposure to soil-dwelling microorganisms, sometimes invoked in the marketing context of SBO probiotics, refers to the general human evolutionary exposure to environmental microorganisms through contact with soil and unprocessed foods — not to the intentional or traditional use of any specific bacterial species. No peer-reviewed or institutional source documents Pseudomonas calcis as a species used in traditional medicine or food fermentation.

Key Constituents and Biological Properties

Calcium Carbonate Precipitation (Biomineralization)

The defining biochemical characteristic of the organism named Pseudomonas calcis — and the basis for its name — is its capacity to induce the precipitation of calcium carbonate minerals. Calcium carbonate (CaCO₃), due to its high biocompatibility, is employed in many pharmaceutical (antacid, dietary supplement for children and postmenopausal women), biological, and biomedical applications; its particles can be found as three different polymorphs: vaterite, aragonite, and calcite.

Microorganisms create favorable chemical conditions for calcium carbonate precipitation through urease and carbonic anhydrase activity, and also promote carbonate mineral precipitation through extracellular polymeric substance (EPS) formation. The formation of calcium carbonate extracellular structures is associated with complex colony morphology and altered diffusion in microbial biofilms; a broad range of extracellular matrix polymers, including functional amyloids, eDNA, and exopolysaccharides, interact with calcium and promote calcium carbonate mineralization.

Research using related Pseudomonas species such as Pseudomonas putida has shown that these organisms produce calcite and vaterite polymorphs of calcium carbonate, confirmed by X-ray diffraction (XRD) analysis. The precipitation process is dependent on bacterial metabolic byproducts that raise local pH and alkalinity, driving carbonate mineral nucleation. These biomineral-precipitation properties are of interest primarily in materials science, construction, and geomicrobiology — not in human nutrition or pharmacology.

Denitrification

As originally classified, Pseudomonas calcis (formerly Bacterium calcis) was described as a denitrifying bacterium — one capable of reducing nitrate or nitrite compounds under anaerobic conditions, a process ecologically important for nitrogen cycling. Drew's early work suggested that marine denitrifying bacteria played an active role in the precipitation of calcium carbonates with a potential geological significance. Denitrifying activity in gut-associated bacteria is a recognized area of microbiome research, though no evidence specifically attributes clinically meaningful denitrification effects to Pseudomonas calcis in a human dietary context.

General Pseudomonas Metabolic Diversity

The members of the genus Pseudomonas demonstrate a great deal of metabolic diversity and are able to colonize a wide range of niches. Various Pseudomonas species are studied for their production of biosurfactants, siderophores, secondary metabolites, and antimicrobial compounds. However, none of these properties have been attributed to Pseudomonas calcis specifically in the peer-reviewed literature reviewed for this article, and no active compounds specific to this organism have been characterized in the context of human dietary supplementation.

Appearance in Dietary Supplement Formulations

Soil-Based Organism (SBO) Probiotics

Pseudomonas calcis appears as one of the listed microbial constituents in certain multi-organism SBO probiotic dietary supplement products. The most documented of these is Prescript-Assist, a commercial preparation. Prescript-Assist lists among its active organisms Pseudomonas calcis, alongside other species including Pseudomonas denitrificans, Pseudomonas fluorescens, Pseudomonas glathei, numerous Bacillus, Arthrobacter, Azotobacter, Azospirillum, Streptomyces, and other soil-dwelling genera.

Prescript-Assist is described as a combination of 28 probiotic microflora "Soil-Based-Organisms (SBOs)" uniquely combined with a humic/fulvic acid prebiotic that enhances SBO proliferation; its microflora are described as Class-1 micro-ecological units typical of those found resident along the healthy human GI tract.

The probiotic component of Prescript-Assist includes 29 soil-based microorganisms (SBOs), described as representative of small, self-regulating ecological units observed during organic-matter breakdowns in soils, sufficient for plant viability in sterilized soils, and categorized as Class 1 etiological agents; the prebiotic component, largely leonardite, is a nutritional medium that enhances SBO proliferation.

The soil-based bacteria in the product are stored in a dry, dormant state meant to be activated via the digestive tract. Unlike other probiotics, Prescript-Assist is described as having inherent viability, meaning the species selected for inclusion are naturally adapted for survival in the human GI tract.

Scientific Evidence by Area of Use

Critical evidentiary limitation: No clinical study, animal study, in vitro study, or systematic review has been identified that examines Pseudomonas calcis as an isolated ingredient. All clinical evidence described below involves the multi-organism Prescript-Assist formula, in which Pseudomonas calcis is one of approximately 29 listed species. It is therefore impossible from the existing literature to attribute any observed effect specifically to Pseudomonas calcis.

Gastrointestinal Health / Irritable Bowel Syndrome (IBS)

The principal clinical evidence concerning the formula containing Pseudomonas calcis involves IBS.

2005 Randomized Controlled Trial (Bittner et al.): The symptomatic efficacy of Prescript-Assist had previously been evaluated clinically only in an open-label study; the 2005 study was conducted primarily to compare the effects of Prescript-Assist with placebo in patients with a diagnosis of IBS, with a secondary methodologic goal of determining the number and nature of symptom clusters characterizing IBS. This was a double-blind, placebo-controlled clinical study in which patients were randomly assigned to receive either Prescript-Assist one 500-mg capsule twice daily (BID) or one placebo capsule BID for 2 weeks. The study identified 3 subsyndromic factors of IBS: general ill feelings/nausea, indigestion/flatulence, and colitis. The probiotic significantly reduced general ill feelings/nausea and indigestion/flatulence compared to placebo in 25 adults over 2 weeks in this randomized, double-blind, placebo-controlled design.

Limitations of the 2005 trial: The trial enrolled only 25 adults, was of only 2 weeks' duration, was not independently replicated, tested a 29-organism blend (making strain attribution impossible), and was conducted by researchers affiliated with the manufacturer's support. The study's small sample size significantly limits statistical power and generalizability.

2007 Open-Label Extension Study (Bittner et al.): The aim of this study was to extend a previous 2-week assessment of the probiotic-prebiotic complex in patients with IBS; in this open-label, partially controlled, 1-year (approximately 14 months) extension study, data were collected from patients who continued treatment following the 2-week study; data were collected at 2 weeks and approximately 60 weeks after the end of the original study; a total of 25 patients entered the 2-week extension and 22 completed the approximately 60-week follow-up (20 women, 2 men; age range, 20–70 years; all white). Results in the control group 2 weeks after crossover to treatment were similar to those from the original study, with reductions in IBS subsyndromes including general ill feelings/nausea (P < 0.001) and indigestion/flatulence (P < 0.001). Based on the results from the 1-year extension study, treatment with this probiotic-prebiotic complex may be an option for short-term (2–4 weeks) and long-term (approximately 60-week) reductions in IBS symptoms.

Limitations of the 2007 extension: This was an open-label, partially controlled extension — not a blinded trial — and is therefore subject to significant placebo and expectation effects. The cohort was exclusively white adults, limiting generalizability. The absence of a concurrent blinded placebo group for the long-term phase substantially weakens conclusions.

Overall IBS evidence assessment: Evidence for the multi-organism SBO blend containing Pseudomonas calcis on IBS symptoms is preliminary and limited to two small studies by the same research group, one of which was a short-duration RCT (n=25, 2 weeks) and the other an open-label extension. Independent replication by separate research groups has not been identified in the reviewed sources. No attribution to Pseudomonas calcis specifically is possible.

Gut Microbiome and Digestive Function (General)

Initially used "to minimize gastritis with/after antibiotics," clinical reports increasingly pointed toward broader applications for the Prescript-Assist formula, including IBS, colitis, and bacterial diarrhea. Sensitive individuals with histamine intolerance or small intestinal bacterial overgrowth (SIBO) are suggested to sometimes tolerate soil-based probiotic formulas better than traditional probiotics. These observations are anecdotal or derive from non-randomized clinical reports rather than controlled trials.

Dosage Forms and Reported Dosages

In the 2005 randomized controlled clinical trial, Prescript-Assist was administered as one 500-mg capsule twice daily (BID) for 2 weeks.

Product labeling for Prescript-Assist suggests taking 1 capsule per day as a dietary supplement for adults. Some product instructions suggest 2 capsules per day for the first 30 days, followed by 1 to 2 capsules per week thereafter, or as recommended by a healthcare professional.

This soil-based pre- and probiotic requires zero refrigeration and is described as having an indefinite shelf life.

No dosage specific to Pseudomonas calcis as an individual organism (e.g., as a colony-forming unit count per dose) has been reported in any source reviewed. The organism is one of approximately 29 constituents in a proprietary blend, and the proportion attributed to each individual species is not disclosed in the publicly available literature or product labeling reviewed.

Body Systems and Health Areas of Association

• Gastrointestinal system: The primary area of association for the SBO formula containing Pseudomonas calcis is GI health, specifically IBS symptom reduction and general gut flora support, based on the Bittner et al. clinical program.
• Geomicrobiology / mineral metabolism: In a purely scientific (non-supplemental) context, Pseudomonas calcis is associated with calcium carbonate biomineralization — the extracellular deposition of CaCO₃ minerals. This is a geomicrobial and materials-science property, not a human health property.
• Nitrogen cycling: As originally described, the organism participates in denitrification, relevant to soil ecology but not to any established human health application.

Safety Considerations

Class 1 Designation and Supplement Listings

The probiotic component of the Prescript-Assist formula, including its 29 soil-based microorganisms, is described as representative of Class 1 etiological agents, meaning they are considered non-pathogenic under standard biosafety classification systems. This classification applies to the formula's organisms as presented by the manufacturer; it has not been independently confirmed for Pseudomonas calcis specifically in peer-reviewed safety assessments.

Genus-Level Safety Concerns

The safety profile of Pseudomonas calcis as an individual organism cannot be assessed from the available literature. However, the broader genus Pseudomonas contains species of known clinical concern. As opportunistic pathogens, Pseudomonas spp. often invade host tissue and cause infection and bacteremia in immunocompromised hosts, including those with HIV/AIDS, cystic fibrosis, bronchiectasis, severe chronic obstructive pulmonary disease, burns, malignancy, or diabetes mellitus. The pathogenic species most frequently implicated is P. aeruginosa, which is taxonomically and genetically distinct from the historical P. calcis.

Pseudomonas aeruginosa is a Gram-negative, aerobic, non-spore-forming rod capable of causing a variety of infections in both immunocompetent and immunocompromised hosts; its predilection to cause infections among immunocompromised hosts, extreme versatility, antibiotic resistance, and a wide range of dynamic defenses makes it an extremely challenging organism to treat in modern medicine. It must be emphasized that this characterization applies to P. aeruginosa, not to P. calcis, and should not be conflated without specific evidence.

No documented cases of infection attributable to Pseudomonas calcis derived from dietary supplement use have been identified in the sources reviewed for this article. Nevertheless, the genus-level context warrants attention, particularly for immunocompromised individuals.

Absence of Regulatory Approval or Monograph

Pseudomonas calcis does not have a safety monograph from the U.S. NIH Office of Dietary Supplements, NCCIH, EFSA, EMA, WHO, German Commission E, ESCOP, or any other regulatory or pharmacopeial body identified in searches for this article. The organism has not been granted GRAS (Generally Recognized As Safe) status by the U.S. FDA as an individual ingredient. No independently published toxicology studies for Pseudomonas calcis were identified.

Interaction Considerations

No drug–supplement interactions specific to Pseudomonas calcis have been characterized in the literature. In the context of the Prescript-Assist multi-organism formula, clinical reports initially indicated usefulness in minimizing gastritis occurring with or after antibiotic use. No systematic evaluation of interactions between the formula or its individual constituents and pharmaceutical agents has been published in peer-reviewed sources reviewed for this article.

Summary of Evidence Quality

The following summarizes the state of evidence as accurately as the reviewed sources permit:

• Identity: Pseudomonas calcis is a historically named denitrifying bacterium first described in 1911. Its current taxonomic validity as a distinct named species is uncertain by contemporary standards.
• Traditional use: None documented.
• Mechanisms: The organism is associated with calcium carbonate biomineralization via denitrification-linked alkalinization of local environments; no mechanisms specific to human health have been characterized.
• Clinical evidence: Nonexistent at the level of Pseudomonas calcis as a standalone ingredient. The multi-organism SBO formula in which it is a listed component (Prescript-Assist) has been evaluated in two small studies (n=25) for IBS, both from the same research group, with preliminary positive findings for symptom reduction. Evidence quality is weak-to-moderate due to small sample sizes, manufacturer involvement, and lack of independent replication.
• Regulatory status: Not assessed as an individual ingredient by any major regulatory or pharmacopeial body.
• Safety: No specific safety data for Pseudomonas calcis as a supplement ingredient. Genus-level concerns about opportunistic pathogenicity in immunocompromised individuals exist for certain other Pseudomonas species, primarily P. aeruginosa.

References

• Boquet E, Boronat A, Ramos-Cormenzana A. Production of Calcite (Calcium Carbonate) Crystals by Soil Bacteria is a General Phenomenon. Nature. 1973;246:527–529.
• Bittner AC, Croffut RM, Stranahan MC. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clinical Therapeutics. 2005;27(6):755–761.
• Bittner AC, Croffut RM, Stranahan MC, Yokelson TN. Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial. Clinical Therapeutics. 2007;29(7):1153–1160.
• Physalix E et al. Physiological and genetic characterization of calcium phosphate precipitation by Pseudomonas species. Scientific Reports. 2018.
• Dhami NK, Reddy MS, Mukherjee A. Application of calcifying bacteria for remediation of stones and cultural heritages. Frontiers in Microbiology. 2014;5:304.
• Costa LMM, Olyveira GM, Salomão. Precipitated calcium carbonate nano-microparticles: applications in drug delivery. MedCrave Online. 2017.
• Government of Canada. Pathogen Safety Data Sheets: Infectious Substances – Pseudomonas spp. Public Health Agency of Canada.
• Kalligeros M, Shehadeh F, Mylonakis E. Pseudomonas aeruginosa Infections. StatPearls. NCBI Bookshelf. 2023.
• Gomila M et al. Phylogenomic Analyses of the Genus Pseudomonas Lead to the Rearrangement of Several Species and the Definition of New Genera. PMC. 2021.
• Zhu T, Dittrich M. The diversity of molecular mechanisms of carbonate biomineralization by bacteria. Discover Materials. Springer Nature. 2020.
• Murgolo S et al. Physiological and genetic characterization of calcium phosphate precipitation by Pseudomonas species. Scientific Reports. 2018.
• Carbonate mineral precipitation induced by microorganisms enriched from cave water and biofilm in a lime-decorated lava tube. Scientific Reports. 2025.
• Bittner AC, Croffut RM, Stranahan MC. Prescript-assist™ probiotic-prebiotic treatment for irritable bowel syndrome. Clinical Therapeutics. ScienceDirect. 2005.
• Bittner AC et al. Prescript-assist™ probiotic-prebiotic treatment for irritable bowel syndrome: 1-year extension. Clinical Therapeutics. ScienceDirect. 2007.